Literature DB >> 22678112

Two-stage extreme phenotype sequencing design for discovering and testing common and rare genetic variants: efficiency and power.

Guolian Kang1, Dongyu Lin, Hakon Hakonarson, Jinbo Chen.   

Abstract

Next-generation sequencing technology provides an unprecedented opportunity to identify rare susceptibility variants. It is not yet financially feasible to perform whole-genome sequencing on a large number of subjects, and a two-stage design has been advocated to be a practical option. In stage I, variants are discovered by sequencing the whole genomes of a small number of carefully selected individuals. In stage II, the discovered variants of a large number of individuals are genotyped to assess associations. Individuals with extreme phenotypes are typically selected in stage I. Using simulated data for unrelated individuals, we explore two important aspects of this two-stage design: the efficiency of discovering common and rare single-nucleotide polymorphisms (SNPs) in stage I and the impact of incomplete SNP discovery in stage I on the power of testing associations in stage II. We applied a sum test and a sum of squared score test for gene-based association analyses evaluating the power of the two-stage design. We obtained the following results from extensive simulation studies and analysis of the GAW17 dataset. When individuals with trait values more extreme than the 99.7-99th quantile were included in stage I, the two-stage design could achieve the same power as or even higher than the one-stage design if the rare causal variants had large effect sizes. In such design, fewer than half of the total SNPs including more than half of the causal SNPs were discovered, which included nearly all SNPs with minor allele frequencies (MAFs) ≥5%, more than half of the SNPs with MAFs between 1% and 5%, and fewer than half of the SNPs with MAFs <1%. Although a one-stage design may be preferable to identify multiple rare variants having small to moderate effect sizes, our observations support using the two-stage design as a cost-effective option for next-generation sequencing studies.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22678112      PMCID: PMC3558993          DOI: 10.1159/000337300

Source DB:  PubMed          Journal:  Hum Hered        ISSN: 0001-5652            Impact factor:   0.444


  24 in total

1.  Are rare variants responsible for susceptibility to complex diseases?

Authors:  J K Pritchard
Journal:  Am J Hum Genet       Date:  2001-06-12       Impact factor: 11.025

2.  A data-adaptive sum test for disease association with multiple common or rare variants.

Authors:  Fang Han; Wei Pan
Journal:  Hum Hered       Date:  2010-04-23       Impact factor: 0.444

3.  Improved power by use of a weighted score test for linkage disequilibrium mapping.

Authors:  Tao Wang; Robert C Elston
Journal:  Am J Hum Genet       Date:  2006-12-21       Impact factor: 11.025

Review 4.  Structural variation in the human genome and its role in disease.

Authors:  Paweł Stankiewicz; James R Lupski
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

5.  Power in the phenotypic extremes: a simulation study of power in discovery and replication of rare variants.

Authors:  Lin T Guey; Jasmina Kravic; Olle Melander; Noël P Burtt; Jason M Laramie; Valeriya Lyssenko; Anna Jonsson; Eero Lindholm; Tiinamaija Tuomi; Bo Isomaa; Peter Nilsson; Peter Almgren; Sekar Kathiresan; Leif Groop; Albert B Seymour; David Altshuler; Benjamin F Voight
Journal:  Genet Epidemiol       Date:  2011-05       Impact factor: 2.135

6.  Asymptotic tests of association with multiple SNPs in linkage disequilibrium.

Authors:  Wei Pan
Journal:  Genet Epidemiol       Date:  2009-09       Impact factor: 2.135

7.  A new testing strategy to identify rare variants with either risk or protective effect on disease.

Authors:  Iuliana Ionita-Laza; Joseph D Buxbaum; Nan M Laird; Christoph Lange
Journal:  PLoS Genet       Date:  2011-02-03       Impact factor: 5.917

8.  Genetic Analysis Workshop 17 mini-exome simulation.

Authors:  Laura Almasy; Thomas D Dyer; Juan Manuel Peralta; Jack W Kent; Jac C Charlesworth; Joanne E Curran; John Blangero
Journal:  BMC Proc       Date:  2011-11-29

9.  A groupwise association test for rare mutations using a weighted sum statistic.

Authors:  Bo Eskerod Madsen; Sharon R Browning
Journal:  PLoS Genet       Date:  2009-02-13       Impact factor: 5.917

10.  Discovery of rare variants via sequencing: implications for the design of complex trait association studies.

Authors:  Bingshan Li; Suzanne M Leal
Journal:  PLoS Genet       Date:  2009-05-15       Impact factor: 5.917

View more
  9 in total

1.  Evaluation of a two-step iterative resampling procedure for internal validation of genome-wide association studies.

Authors:  Guolian Kang; Wei Liu; Cheng Cheng; Carmen L Wilson; Geoffrey Neale; Jun J Yang; Kirsten K Ness; Leslie L Robison; Melissa M Hudson; Deo Kumar Srivastava
Journal:  J Hum Genet       Date:  2015-09-17       Impact factor: 3.172

2.  Phenotypic extremes in rare variant study designs.

Authors:  Gina M Peloso; Daniel J Rader; Stacey Gabriel; Sekar Kathiresan; Mark J Daly; Benjamin M Neale
Journal:  Eur J Hum Genet       Date:  2015-09-09       Impact factor: 4.246

3.  Low-, high-coverage, and two-stage DNA sequencing in the design of the genetic association study.

Authors:  Chao Xu; Kehao Wu; Ji-Gang Zhang; Hui Shen; Hong-Wen Deng
Journal:  Genet Epidemiol       Date:  2016-11-04       Impact factor: 2.135

4.  Focused Analysis of Exome Sequencing Data for Rare Germline Mutations in Familial and Sporadic Lung Cancer.

Authors:  Yanhong Liu; Farrah Kheradmand; Caleb F Davis; Michael E Scheurer; David Wheeler; Spiridon Tsavachidis; Georgina Armstrong; Claire Simpson; Diptasri Mandal; Elena Kupert; Marshall Anderson; Ming You; Donghai Xiong; Claudio Pikielny; Ann G Schwartz; Joan Bailey-Wilson; Colette Gaba; Mariza De Andrade; Ping Yang; Susan M Pinney; Christopher I Amos; Margaret R Spitz
Journal:  J Thorac Oncol       Date:  2016-01       Impact factor: 15.609

Review 5.  Cancer pharmacogenomics: strategies and challenges.

Authors:  Heather E Wheeler; Michael L Maitland; M Eileen Dolan; Nancy J Cox; Mark J Ratain
Journal:  Nat Rev Genet       Date:  2012-11-27       Impact factor: 53.242

6.  Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk.

Authors:  Rui Fu; Jia-Tao Zhang; Rong-Rong Chen; Hong Li; Zai-Xian Tai; Hao-Xiang Lin; Jian Su; Xiang-Peng Chu; Chao Zhang; Zhen-Bin Qiu; Zi-Hao Chen; Wen-Fang Tang; Song Dong; Xue-Ning Yang; Guo-Qing Zhang; Guo-Ping Zhao; Yi-Long Wu; Wen-Zhao Zhong
Journal:  Transl Lung Cancer Res       Date:  2022-04

7.  Rare deleterious germline variants and risk of lung cancer.

Authors:  Yanhong Liu; Jun Xia; James McKay; Spiridon Tsavachidis; Xiangjun Xiao; Margaret R Spitz; Chao Cheng; Jinyoung Byun; Wei Hong; Yafang Li; Dakai Zhu; Zhuoyi Song; Susan M Rosenberg; Michael E Scheurer; Farrah Kheradmand; Claudio W Pikielny; Christine M Lusk; Ann G Schwartz; Ignacio I Wistuba; Michael H Cho; Edwin K Silverman; Joan Bailey-Wilson; Susan M Pinney; Marshall Anderson; Elena Kupert; Colette Gaba; Diptasri Mandal; Ming You; Mariza de Andrade; Ping Yang; Triantafillos Liloglou; Michael P A Davies; Jolanta Lissowska; Beata Swiatkowska; David Zaridze; Anush Mukeria; Vladimir Janout; Ivana Holcatova; Dana Mates; Jelena Stojsic; Ghislaine Scelo; Paul Brennan; Geoffrey Liu; John K Field; Rayjean J Hung; David C Christiani; Christopher I Amos
Journal:  NPJ Precis Oncol       Date:  2021-02-16

8.  Comparison of mixed model based approaches for correcting for population substructure with application to extreme phenotype sampling.

Authors:  Maryam Onifade; Marie-Hélène Roy-Gagnon; Marie-Élise Parent; Kelly M Burkett
Journal:  BMC Genomics       Date:  2022-02-04       Impact factor: 3.969

Review 9.  A Systematic Review of Extreme Phenotype Strategies to Search for Rare Variants in Genetic Studies of Complex Disorders.

Authors:  Sana Amanat; Teresa Requena; Jose Antonio Lopez-Escamez
Journal:  Genes (Basel)       Date:  2020-08-25       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.